X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs NOVARTIS - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB NOVARTIS DR. REDDYS LAB/
NOVARTIS
 
P/E (TTM) x 27.2 346.5 7.8% View Chart
P/BV x 2.8 17.1 16.4% View Chart
Dividend Yield % 1.0 1.7 59.8%  

Financials

 DR. REDDYS LAB   NOVARTIS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
NOVARTIS
Mar-16
DR. REDDYS LAB/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs4,383982 446.3%   
Low Rs2,750556 494.4%   
Sales per share (Unadj.) Rs920.1252.9 363.8%  
Earnings per share (Unadj.) Rs126.162.1 202.9%  
Cash flow per share (Unadj.) Rs183.063.3 289.1%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %0.61.3 43.1%  
Book value per share (Unadj.) Rs685.8363.6 188.6%  
Shares outstanding (eoy) m170.6131.96 533.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.93.0 127.5%   
Avg P/E ratio x28.312.4 228.5%  
P/CF ratio (eoy) x19.512.2 160.4%  
Price / Book Value ratio x5.22.1 245.9%  
Dividend payout %15.916.1 98.6%   
Avg Mkt Cap Rs m608,48124,580 2,475.5%   
No. of employees `00021.70.8 2,881.5%   
Total wages/salary Rs m31,8741,801 1,769.6%   
Avg. sales/employee Rs Th7,244.410,748.9 67.4%   
Avg. wages/employee Rs Th1,470.92,395.2 61.4%   
Avg. net profit/employee Rs Th992.82,641.1 37.6%   
INCOME DATA
Net Sales Rs m156,9788,083 1,942.0%  
Other income Rs m2,693829 324.7%   
Total revenues Rs m159,6718,913 1,791.5%   
Gross profit Rs m34,587234 14,768.1%  
Depreciation Rs m9,70537 26,444.1%   
Interest Rs m8242 45,777.8%   
Profit before tax Rs m26,7511,025 2,609.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m5,237752 696.4%   
Profit after tax Rs m21,5141,986 1,083.2%  
Gross profit margin %22.02.9 760.4%  
Effective tax rate %19.673.4 26.7%   
Net profit margin %13.724.6 55.8%  
BALANCE SHEET DATA
Current assets Rs m118,20112,678 932.3%   
Current liabilities Rs m68,3682,433 2,810.0%   
Net working cap to sales %31.7126.7 25.0%  
Current ratio x1.75.2 33.2%  
Inventory Days Days6033 183.5%  
Debtors Days Days9722 430.8%  
Net fixed assets Rs m72,26569 104,429.2%   
Share capital Rs m853160 533.8%   
"Free" reserves Rs m111,54811,460 973.4%   
Net worth Rs m117,00911,621 1,006.8%   
Long term debt Rs m10,6900-   
Total assets Rs m200,10414,400 1,389.7%  
Interest coverage x33.5570.5 5.9%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.6 139.7%   
Return on assets %11.213.8 80.9%  
Return on equity %18.417.1 107.6%  
Return on capital %21.623.6 91.6%  
Exports to sales %46.30.7 6,211.4%   
Imports to sales %9.018.6 48.1%   
Exports (fob) Rs m72,61860 120,627.9%   
Imports (cif) Rs m14,0501,503 935.0%   
Fx inflow Rs m75,405186 40,475.0%   
Fx outflow Rs m27,1151,821 1,489.2%   
Net fx Rs m48,290-1,635 -2,954.4%   
CASH FLOW
From Operations Rs m40,4762,531 1,599.3%  
From Investments Rs m-19,421-8,270 234.8%  
From Financial Activity Rs m-17,009-386 4,409.9%  
Net Cashflow Rs m4,046-6,125 -66.1%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 2.0 270.0%  
FIIs % 35.3 1.6 2,206.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 21.5 71.2%  
Shareholders   75,885 41,647 182.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  UNICHEM LAB  CADILA HEALTHCARE  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; IT Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the IT sector and power sector witnessing maximum selling pressure.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 21, 2017 12:32 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS